The Neuroendocrine Tumors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuroendocrine Tumors Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuroendocrine Tumors Market.

Some of the key takeaways from the Neuroendocrine Tumors Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Neuroendocrine Tumors treatment therapies with a considerable amount of success over the years. 
• Neuroendocrine Tumors companies working in the treatment market are Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others, are developing therapies for the Neuroendocrine Tumors treatment 

• Emerging Neuroendocrine Tumors therapies in the different phases of clinical trials are- ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others are expected to have a significant impact on the Neuroendocrine Tumors market in the coming years.   
• In May 2023, Amgen commenced a Phase III study involving tarlatamab versus standard of care for individuals experiencing relapsed small cell lung cancer after initial platinum-based chemotherapy. This trial is actively enrolling participants and is projected to conclude by June 2025, aiming for an estimated enrollment of 700 participants.
• In March 2023, RayzeBio, Inc., a company focused on targeted radiopharmaceuticals for solid tumors, reported the conclusion of enrollment for the Phase 1b segment within the ACTION-1 Phase 1b/3 trial evaluating RYZ101. This trial involves patients with SSTR+ gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who experienced progression after receiving Lutetium-177 labeled somatostatin analog therapy.
• In March 2023, NUCLIDIUM revealed that the Neuroendocrine Tumors Research Foundation (“NETRF”) has chosen the company along with its collaborative partner, the University Hospital Basel (Universitätsspital Basel, “USB”), as recipients of its Investigator Award. This funding will aid in commencing and conducting a Phase 1 clinical trial featuring TraceNETTM, an innovative copper-based radiodiagnostic tool designed for detecting neuroendocrine tumors (NET).

Neuroendocrine Tumors Overview

The specialized cells of the body’s neuroendocrine system are the starting point of a neuroendocrine cancer, also known as a neuroendocrine tumor (NET) or neuroendocrine neoplasm. These cells combine characteristics of nerve cells and endocrine cells that produce hormones.

Get a Free Sample PDF Report to know more about Neuroendocrine Tumors Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuroendocrine-tumors-pipeline-insight

Emerging Neuroendocrine Tumors Drugs Under Different Phases of Clinical Development Include:

• ITI 3000: Immunomic Therapeutics
• Paltusotine: Crinetics Pharmaceuticals
• PM8002: Biotheus
• GP-2250: Panavance Therapeutics
• BG-P-TAT: Nano Pharmaceuticals
• OBT-620: Oxford BioTherapeutics
• SVV-001: Seneca Therapeutics
• Tarlatamab: Amgen
• PNT2003: POINT Biopharma
• RYZ101: RayzeBio

Neuroendocrine Tumors Route of Administration

Neuroendocrine Tumors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Neuroendocrine Tumors Molecule Type

Neuroendocrine Tumors Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Neuroendocrine Tumors Pipeline Therapeutics Assessment

• Neuroendocrine Tumors Assessment by Product Type
• Neuroendocrine Tumors By Stage and Product Type
• Neuroendocrine Tumors Assessment by Route of Administration
• Neuroendocrine Tumors By Stage and Route of Administration
• Neuroendocrine Tumors Assessment by Molecule Type
• Neuroendocrine Tumors by Stage and Molecule Type

DelveInsight’s Neuroendocrine Tumors Report covers around 60+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Neuroendocrine Tumors product details are provided in the report. Download the Neuroendocrine Tumors pipeline report to learn more about the emerging Neuroendocrine Tumors therapies

Some of the key companies in the Neuroendocrine Tumors Therapeutics Market include:

Key companies developing therapies for Neuroendocrine Tumors are – Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, and others.

Neuroendocrine Tumors Pipeline Analysis:

The Neuroendocrine Tumors pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Neuroendocrine Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuroendocrine Tumors Treatment.
• Neuroendocrine Tumors key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Neuroendocrine Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuroendocrine Tumors market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuroendocrine Tumors drugs and therapies

Neuroendocrine Tumors Pipeline Market Drivers

• Rising prevalence of the disease, growing Research and Development Activities are some of the important factors that are fueling the Neuroendocrine Tumors Market.

Neuroendocrine Tumors Pipeline Market Barriers

• However, limited Awareness and Under diagnosis, heterogeneity and Complexity and other factors are creating obstacles in the Neuroendocrine Tumors Market growth.

Scope of Neuroendocrine Tumors Pipeline Drug Insight    

• Coverage: Global
• Key Neuroendocrine Tumors Companies: Immunomic Therapeutics, Crinetics Pharmaceuticals, Biotheus, Panavance Therapeutics, Nano Pharmaceuticals, Oxford BioTherapeutics, Seneca Therapeutics, Amgen, POINT Biopharma, RayzeBio, and others
• Key Neuroendocrine Tumors Therapies: ITI 3000, Paltusotine, PM8002, GP-2250, BG-P-TAT, OBT-620, SVV-001, Tarlatamab, PNT2003, RYZ101, and others
• Neuroendocrine Tumors Therapeutic Assessment: Neuroendocrine Tumors current marketed and Neuroendocrine Tumors emerging therapies
• Neuroendocrine Tumors Market Dynamics: Neuroendocrine Tumors market drivers and Neuroendocrine Tumors market barriers 

Request for Sample PDF Report for Neuroendocrine Tumors Pipeline Assessment and clinical trials

Table of Contents

1. Neuroendocrine Tumors Report Introduction

2. Neuroendocrine Tumors Executive Summary

3. Neuroendocrine Tumors Overview

4. Neuroendocrine Tumors- Analytical Perspective In-depth Commercial Assessment

5. Neuroendocrine Tumors Pipeline Therapeutics

6. Neuroendocrine Tumors Late Stage Products (Phase II/III)

7. Neuroendocrine Tumors Mid Stage Products (Phase II)

8. Neuroendocrine Tumors Early Stage Products (Phase I)

9. Neuroendocrine Tumors Preclinical Stage Products

10. Neuroendocrine Tumors Therapeutics Assessment

11. Neuroendocrine Tumors Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuroendocrine Tumors Key Companies

14. Neuroendocrine Tumors Key Products

15. Neuroendocrine Tumors Unmet Needs

16 . Neuroendocrine Tumors Market Drivers and Barriers

17. Neuroendocrine Tumors Future Perspectives and Conclusion

18. Neuroendocrine Tumors Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com